Reputable Factory Supply 85622-93-1 with Efficient Transportation, Buy Quality Temozolomide

Product Details

Quick Details

CasNo： 85622-93-1
Purity： 99%

Reputable Factory Supply 85622-93-1 with Efficient Transportation, Buy Quality Temozolomide

Molecular Formula:C6H6N6O2
Molecular Weight:194.153
Appearance/Colour:Off-white to light-pink crystalline solid
Melting Point:212 °C dec.
Boiling Point:526.6 °C at 760 mmHg
PKA:14.77±0.20(Predicted)
Flash Point:272.3 °C
PSA：108.17000
Density:1.97 g/cm³
LogP:-1.37780

Temozolomide(Cas 85622-93-1) Usage

Description

Temozolomide is a type of chemotherapy. It is also known as Temodal. It is a treatment for: certain types of brain tumour such as glioblastoma and astrocytoma. neuroendocrine tumours.

Uses

Temozolomide is used to treat specific types of brain cancer (eg, glioblastoma multiforme, anaplastic astrocytoma) in patients whose tumors have returned or whose tumors have just been diagnosed. It belongs to the group of medicines known as antineoplastics (cancer medicines). Take this medicine at the same time each day, either with or without food. Temozolomide often causes nausea and vomiting. However, it is very important that you continue to take the medicine, even if you begin to feel ill. You may take the medicine on an empty stomach or at bedtime may help to lessen the nausea.

InChI:InChI=1/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)

85622-93-1 Relevant articles

Alternative syntheses of the antitumour drug temozolomide avoiding the use of methyl isocyanate

Wang,Stevens,Thomson

, p. 1687 - 1688 (1994)

Ethyl (8-carbamoyl-3,4-dihydro-4-oxoimid...

Identification and physicochemical characteristics of temozolomide process-related impurities

Laszcz, Marta,Kubiszewski, Marek,Jedynak, Lukasz,Kaczmarska, Monika,Kaczmarek, Lukasz,Luniewski, Wojciech,Gabarski, Krzysztof,Witkowska, Anna,Kuziak, Krzysztof,Malinska, Maura

, p. 15344 - 15356 (2013)

In this article the crystal structures o...

Current and future developments in the use of temozolomide for the treatment of brain tumours

R Stupp, M Gander, S Leyvraz, E Newlands

The lancet oncology, 2001

Temozolomide, an alkylating agent that can be administered orally, has been approved for the treatment of recurrent malignant glioma on a daily schedule for 5-day cycles. Continuous administration schedules with a higher dose intensity are being explored, but an improvement in efficiency remains to be shown.

Mechanisms of disease: temozolomide and glioblastoma—look to the future

MM Mrugala, MC Chamberlain

, Nature clinical practice Oncology, 2008

This study created a new standard of adjuvant treatment, using concurrent and sequential temozolomide in the initial therapy of glioblastoma. Several preliminary studies have been initiated to address the issue of resistance and suppression of MGMT activity, and have used alternative temozolomide dosing schedules and O6-guanine mimetic agents as substrates for MGMT.

85622-93-1 Upstream products

624-83-9
methyl isocyanate
7008-85-7
5-diazoimidazole-4-carboxamide
157467-00-0
(8-Carbamoyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazin-3-yl)-acetic acid 2-thioxo-2H-pyridin-1-yl ester
77-78-1
dimethyl sulfate